Neuropilin-1 cooperates with PD-1 in CD8
Cancer
Immunology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 Jun 2022
17 Jun 2022
Historique:
received:
21
02
2021
revised:
25
07
2021
accepted:
29
04
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
epublish
Résumé
Targeting immune checkpoints, such as Programmed cell Death 1 (PD1), has improved survival in cancer patients by restoring antitumor immune responses. Most patients, however, relapse or are refractory to immune checkpoint blocking therapies. Neuropilin-1 (NRP1) is a transmembrane glycoprotein required for nervous system and angiogenesis embryonic development, also expressed in immune cells. We hypothesized that NRP1 could be an immune checkpoint co-receptor modulating CD8
Identifiants
pubmed: 35874918
doi: 10.1016/j.isci.2022.104353
pii: S2589-0042(22)00624-1
pmc: PMC9301874
doi:
Types de publication
Journal Article
Langues
eng
Pagination
104353Informations de copyright
© 2022.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15016-21
pubmed: 18809920
J Exp Med. 2013 Apr 8;210(4):757-74
pubmed: 23530125
Nature. 2013 Sep 12;501(7466):252-6
pubmed: 23913274
Cancer Res. 2015 Sep 15;75(18):3800-11
pubmed: 26208901
J Neurobiol. 1996 Jan;29(1):1-17
pubmed: 8748368
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Trends Immunol. 2014 Feb;35(2):51-60
pubmed: 24210163
Adv Exp Med Biol. 2002;515:55-69
pubmed: 12613543
J Exp Med. 2012 Jun 4;209(6):1201-17
pubmed: 22641383
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
J Exp Med. 2012 Oct 22;209(11):2001-16
pubmed: 23045606
Nat Immunol. 2020 Sep;21(9):1010-1021
pubmed: 32661362
Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
Biochem J. 2008 Apr 15;411(2):211-26
pubmed: 18363553
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
Nat Commun. 2019 Jul 26;10(1):3345
pubmed: 31350404
Nat Rev Immunol. 2013 Nov;13(11):802-14
pubmed: 24319778
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
JCI Insight. 2019 Jun 6;4(11):
pubmed: 31167976
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Immunity. 2007 Jul;27(1):111-22
pubmed: 17629517
Dev Cell. 2003 Jul;5(1):45-57
pubmed: 12852851
Nat Immunol. 2013 Jun;14(6):603-10
pubmed: 23644506
mSphere. 2019 May 22;4(3):
pubmed: 31118303
Nat Immunol. 2010 Jul;11(7):594-600
pubmed: 20512151
Nat Immunol. 2002 May;3(5):477-82
pubmed: 11953749
PLoS One. 2014 Oct 24;9(10):e110707
pubmed: 25343644
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
J Pediatr. 2017 Jun;185:160-166.e1
pubmed: 28284480